Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country

Medical Journal of Australia

Volumn 194, Issue 11, 2011, Pages 602-604

  Goh, Tze Liang ^a   Towns, Cindy R ^a   Jones, Katharine L ^b   Freeman, Joshua T ^c   Wong, Colin S ^a  

^a DUNEDIN HOSPITAL   (New Zealand)

^b CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^c Microbiology Department   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KATG PROTEIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ADULT; ARTICLE; ASPIRATION BIOPSY; BACTERIUM ISOLATE; CASE REPORT; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG SENSITIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; HUMAN; IMMIGRANT; LUNG FIBROSIS; MALE; MYANMAR; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEW ZEALAND; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; SPUTUM EXAMINATION; THORAX RADIOGRAPHY;

EID: 79958800652     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb03115.x     Document Type: Article

References (12)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241599191 _eng.pdf (accessed Jul 2010).
2. Lange C, Yew WW, Migliori GB, Raviglione M. The European Respiratory Journal targets tuberculosis. Eur Respir J 2010; 36: 714-715.
3. World Health Organization. WHO Country Cooperation Strategy 2008-2011: Myanmar. New Delhi: WHO Country Office for Myanmar, 2008. www.searo.who.int/LinkFiles/Myanmar-Cyclone_CCS_Myanmar-19Feb.pdf (accessed Jul 2010).
4. Lopez L, Sexton K, Heffernan H. Tuberculosis in New Zealand: annual report 2009. (Prepared by the Institute of Environmental Science and Research Limited for the Ministry of Health.) MOH, 2010. http:// www.surv.esr.cri.nz/PDF_surveillance/AnnTBReports/TBAnnualReport2009.pdf (accessed Mar 2011).
5. World Health Organization. Tuberculosis control in the Western Pacific region: 2009 report. Geneva: WHO, 2009. http://www.wpro.who.int/NR/ rdonlyres/2894B832-5677-4BB1-B01F-1962551F9304/0/tbcontrol_2009.pdf (accessed Jul 2010).
6. Communicable Diseases Branch, NSW Department of Health. Communicable Diseases Report, NSW, September and October 2010. N S W Public Health Bull 2010; 21: 274-279.
7. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
8. Madariaga MG, Lalloo UG, Swindells S. Extensively drug-resistant tuberculosis. Am J Med 2008; 121: 835-844.
9. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: WHO 2008. http://whqlibdoc.who.int/publications/2008/9789241547581 _eng.pdf (accessed Jul 2010).
10. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
11. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22: 167-173.
12. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systemic review by TBNET. Eur Respir J 2009; 33: 871-881.